<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786081</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1015-05</org_study_id>
    <secondary_id>InnovaTV 205</secondary_id>
    <secondary_id>MK3475 KN 834</secondary_id>
    <nct_id>NCT03786081</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tisotumab Vedotin Monotherapy &amp; in Combination With Other Cancer Agents in Subjects With Cervical Cancer</brief_title>
  <official_title>A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination&#xD;
      with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB&#xD;
      cervical cancer.&#xD;
&#xD;
      The trial consists of two-parts a dose escalation part and an expansion part. The expansion&#xD;
      part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the&#xD;
      combinations have been determined in the dose escalation part.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose escalation part will occur in cervical cancer subjects who have progressed during or&#xD;
      after standard of care therapy and who are intolerant or ineligible to receive standard of&#xD;
      care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and&#xD;
      bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin&#xD;
      + carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed&#xD;
      doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.&#xD;
&#xD;
      The dose expansion part will consist of subjects with recurrent or stage IVB cervical cancer,&#xD;
      who have not received prior systemic therapy for their recurrent or stage IVB disease, Arms D&#xD;
      and E being treated with tisotumab vedotin + carboplatin or tisotumab vedotin +&#xD;
      pembrolizumab, respectively, or subjects, who have progressed on or after standard of care&#xD;
      treatments, Arm F treated with tisotumab vedotin + pembrolizumab and Arm G treated with&#xD;
      tisotumab vedotin alone. Subjects enrolled to Arms D, E, and F will receive the RP2D of&#xD;
      tisotumab vedotin established in the dose escalation part. Subjects enrolled to Arm G will&#xD;
      receive tisotumab vedotin weekly for three weeks and 1 week off (28 day treatment cycle).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose escalation: Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>DLTs will be identified during the first treatment cycles (21 days cycles)</time_frame>
    <description>To establish the MTD and RP2D of tisotumab vedotin in combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion: Evaluate the antitumor activity of tisotumab vedotin monotherapy and in combination in subjects with cervical cancer</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Objective Response Rate (ORR) based upon RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Frequency, duration, and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Objective Response Rate (ORR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Duration of Response (DOR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time to Response (TTR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Progression free survival (PFS) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G: Tisotumab vedotin monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tisotumab Vedotin</intervention_name>
    <description>i.v.</description>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>G: Tisotumab vedotin monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>i.v.</description>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>i.v.</description>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>i.v.</description>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on&#xD;
             or after standard of care treatments or are ineligible or intolerant to standard of&#xD;
             care for recurrent or stage IVB cervical cancer (Arms A, B and C only).&#xD;
&#xD;
          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have&#xD;
             received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D and&#xD;
             E only).&#xD;
&#xD;
          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on&#xD;
             or after at least one but no more than two prior systemic therapies for recurrent or&#xD;
             stage IVB cervical cancer (Arm F and G only).&#xD;
&#xD;
          -  Must have baseline measurable disease per RECIST v1.1.&#xD;
&#xD;
          -  Must be at least 18 years of age on the day of signing informed consent (All Arms).&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All&#xD;
             Arms).&#xD;
&#xD;
          -  Is not pregnant, breastfeeding, or expecting to conceive children within the projected&#xD;
             duration of the trial and for at least 6 months after the last trial treatment&#xD;
             administration&#xD;
&#xD;
          -  Women of childbearing potential must agree to use adequate contraception during and&#xD;
             for 6 months after the last dose of trial treatment administration.&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) indicating the trial subject understands the&#xD;
             purpose of and procedures required for the trial and are willing to participate in the&#xD;
             trial (All Arms).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has clinically relevant bilateral hydronephrosis which cannot be alleviated by&#xD;
             ureteral stents or percutaneous drainage. (All Arms)&#xD;
&#xD;
          -  Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral&#xD;
             hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal&#xD;
             surgery are permitted. (All Arms)&#xD;
&#xD;
          -  Has clinically significant bleeding issues or risks&#xD;
&#xD;
          -  Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or&#xD;
             more) (Arm A only)&#xD;
&#xD;
          -  Recent (within 4 weeks of first dose of trial treatment) clinically significant&#xD;
             gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arm A only)&#xD;
&#xD;
          -  Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing&#xD;
             complications that require medical intervention (Arm A only)&#xD;
&#xD;
          -  Has active ocular surface disease at baseline. Subjects with prior history of&#xD;
             cicatricial conjunctivitis are ineligible (All Arms).&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Requires anti-coagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Research and Education Institute</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Infant Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven,</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Loverval</city>
        <zip>6280</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>12851</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>5072</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D07 R2WY D</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cannizzaro</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Medical Research</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMC Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Adana Application and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>01220</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Ankara Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <state>South Glamorgan</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital- Sutton</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Tisotumab vedotin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

